

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (Currently amended) A cell-free immunoreactive Integrin Linked Kinase (ILK).
2. (Original) An immunoreactive Integrin Linked Kinase according to claim 1, wherein the kinase has a molecular weight of roughly 59 kDA as determined by SDS PAGE.
3. (Currently amended) An immunoreactive Integrin Linked Kinase according to claim 1 ~~or claim 2~~, wherein the kinase is detectable in mammalian serum by Western blotting with a polyclonal antibody raised against the kinase domain of ILK.
4. (Currently amended) An immunoreactive Integrin Linked Kinase according to ~~any one of claims claim 1 to 3~~, wherein the kinase is detectable in mammalian (a) peritoneal fluid by Western blotting with immunoaffinity-purified polyclonal anti-ILK corresponding to the kinase domain of human ILK followed by peroxidase labelled secondary antibody, (b) tissue-conditioned medium by Western blotting using ILK antibody; or (c) serum or peritoneal fluid by immunoprecipitation on protein in 95% acetone:ethanol (1:1) with capture by antibody against ILK and immunoprecipitation ~~visualised~~ visualized by Western blotting.
5. (Currently amended) ~~Use of the kinase~~ The ILK according to ~~any preceding claim-as 1, which is~~ a biomarker for cancer.
6. (Currently amended) A method of detection of cancer, comprising determining the presence or absence of immunoreactive ILK (irILK) ~~irILK~~ in a sample of a biological fluid from a subject, wherein the presence of irILK is an indication of cancer.
7. (Currently amended) A method according to claim 6, for ~~of monitoring~~ the efficacy of a treatment for cancer, comprising carrying out periodic tests, each test comprising determining the concentration or activity of irILK in a sample of a biological fluid from a

subject, wherein a decrease in irILK concentration or activity between tests is indicative of the efficacy of any treatment.

8. (Currently amended) A method according to claim 6, for detecting recurrence of cancer, comprising determining the presence or absence of irILK in a sample of a biological fluid from a subject who has had cancer, wherein the presence of irILK indicates recurrence of cancer.

9. (Currently amended) A method according to claim 6, for ~~of~~ assessing the severity of cancer, comprising determining quantitatively ~~quantitatively determining~~ the amount or activity of irILK in a sample of a biological fluid from a subject, and correlating results with those previously determined for various grades or stages of cancer or ~~correlating results with one~~ or more other markers of cancer.

10. (Original) A method according to claim 9, wherein the other marker of cancer is CA125.

11. (Currently amended) A kit for carrying out ~~any one of the methods~~ method of claims claim 6 to 10, said kit comprising means for detecting irILK in biological fluid.

12. (Original) A kit according to claim 11, comprising an anti-ILK antibody.

13. (Currently amended) ~~Use of irILK according to any one of claims 1 to 5 or a A~~ kit according to claim 11 ~~or claim 12 in~~ for the diagnosis of cancer or ~~study of~~ determining the efficacy of treatment of cancer.

14. (Canceled)

15. (Currently amended) A method of treatment or prevention of cancer comprising administering to a patient determined as suffering therefrom or at risk of developing cancer an agent capable of blocking the increased expression of ILK, or the effect of increased expression of ILK.

16. (Canceled)

17. (Currently amended) A method according to claim 15 ~~or claim 16~~, wherein the agent capable of blocking the increased expression of ILK comprises an antisense nucleic acid for use in a gene therapy approach.

18. (Currently amended) A method according to claim 15 ~~or claim 16~~, wherein the agent capable of blocking the effect of increased expression of ILK comprises an anti-ILK antibody or an antagonist of ILK activity.

19. (Currently amended) ~~Use of A pharmaceutical composition for use in treating cancer which comprises~~ an agent capable blocking the increased expression of ILK, or the effect of increased expression of ILK, ~~and a pharmaceutically acceptable carrier in the manufacture of a medicament for use in treating cancer.~~

20. (Currently amended) ~~The~~ A method according to ~~any one of claims~~ claim 6, ~~to 10~~ wherein the sample of biological fluid comprises whole blood, plasma, serum or peritoneal fluid, ascites, or medium used to perfuse ovarian biopsies, termed tissue conditioned medium.

21. (Currently amended) A method ~~or use~~ according to ~~any one of claims~~ claim 6 to ~~10 and 13 to 20~~, wherein the cancer is present in a mammal.

22. (Original) A method according to claim 21, wherein the mammal is a human.

23. (Currently amended) A method according to ~~any one of claims 6 to 10 and 13 to 22~~ claim 15, wherein the cancer is one in which ILK expression is increased.

24. (Original) A method according to claim 23, wherein the cancer is selected from Ewing's sarcoma, primitive neuroectodermal tumor, medulloblastoma, neuroblastoma, prostate cancer and colon cancer.

25. (Original) A method according to claim 23, wherein the cancer is ovarian cancer.